News

Steven Bair, MD, and colleagues evaluated long-term outcomes across different first-line treatment regimens for elderly patients with DLBCL, including standard dose R-CHOP, reduced dose R-CHOP, and non-anthracycline alternative regimens.

Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.

Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...

Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.

Study on real-world data on patients with chronic lymphocytic leukemia investigated the outcomes for both Black and White patients.

The Journal of Clinical Pathways editorial team is pleased to announce that effective immediately, all submissions to our journal should be uploaded to our new online manuscript submission service, Editorial Manager.

The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.

Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...

The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...

Results from NCCN's recent survey of cancer centers reveals a persisting shortage of chemotherapy drugs within the US, with 72% of centers reporting a shortage of carboplatin and 59% facing challenges with obtaining cisplatin.